Navigation Links
New Details Presented at the World Parkinson Congress on Neurologix's Successful Phase 2 Trial of Gene Therapy for Parkinson's Disease
Date:10/1/2010

perienced statistically significant and clinically meaningful improvements in off-medication motor scores compared to control subjects who received sham surgery.  Patients enrolled in the trial had moderate to advanced PD and were not adequately responsive to current therapies.  

"We are very pleased that Dr. Lewitt had the opportunity to provide more information about our study methodology and some further details as to the nature of the improvements seen in patients treated in our Phase 2 study.  We remain confident in our study results, which we feel confirm that NLX-P101 has great potential to offer an important new therapy for patients with Parkinson's disease," said Clark A. Johnson, President and Chief Executive Officer of the Company.  

Mr. Johnson added, "We continue to believe that the best venue for the full disclosure of our Phase 2 results would be in a respected peer-reviewed medical or scientific journal.  All of the major details of our previous pre-clinical and clinical studies have been published in leading journals, including Science, The Lancet and the Proceedings of the National Academy of Sciences.  We believe that the credibility provided by these publications enhance the value of our product and of our company."

Neurologix, Inc. is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of gene transfer therapies for serious disorders of the brain and central nervous system (CNS).  Neurologix's investigational AAV (adeno-associated virus) vector gene therapy, NLX-P101, is a novel, non-dopaminergic approach that uses an inhibitory gene (glutamic acid decarboxylase or "GAD") to selectively alter the neural circuitry affected in PD and, thereby, normalize brain physiology.  Neurologix's technology is the only gene therapy strategy currently in development which bypasses the dopamine system.  

Neurologix an
'/>"/>

SOURCE Neurologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. PulmoBioTech Announces Details of Its Regulatory Approval Experiments
2. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
3. Newly Published Article Details How PGS Techniques Directly Effect Successful Pregnancy Outcomes
4. Kendle Announces Details Regarding Third Quarter 2009 Earnings Conference Call and Webcast
5. Young Innovations, Inc. Provides Third Quarter Conference Call Details
6. Cord Blood America Details Las Vegas Laboratory Progress in Analyst Interview
7. Young Innovations, Inc. Provides 4th Quarter Conference Call Details
8. Kendle Announces Details Regarding Second Quarter 2010 Earnings Conference Call and Webcast
9. Young Innovations, Inc. Provides 2nd Quarter Conference Call Details
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , Oct. 17, 2014 Research ... "Research and Development Prospect of China Dialysis ... Based on the 2013 version, this ... policies about dialysis industry and the relevant effect ... about dialysis industry segmentations. Moreover, it analyzes Chinese ...
(Date:10/17/2014)... , Oct. 17, 2014 The ... Medical Technology Policy: The Green Park ... FDA, public and private payers, medical device and ... and other experts January 12, 2015 at its ... value of weight loss treatments.  Participants will discuss ...
(Date:10/17/2014)... -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" ... biopharmaceutical company in China , ... from the China Food and Drug Administration (the ... concentrate ("PCC") at its Shandong Taibang facility. The ... facility for Good Manufacturing Practices ("GMP") compliance in ...
Breaking Medicine Technology:Research and Development Prospect of China Dialysis Market, 2014-2018 2Research and Development Prospect of China Dialysis Market, 2014-2018 3Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 2China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 3
... Network, Inc. (Other OTC: CNWI.PK) (the "Company") today announced that ... "Reverse Stock Split"). The Reverse Stock Split will take effect ... 2011 (the "Effective Date"). On the Effective Date, the Company,s ... approximately 20 business days, after which it will revert to ...
... SAN FRANCISCO, Calif., May 5, 2011 Rigel Pharmaceuticals, Inc. ... the company,s chief financial officer, is scheduled to present a ... Care Conference in Las Vegas on Tuesday, May 10th at ... The presentation will be webcast live and can ...
Cached Medicine Technology:Cardiac Network Announces Reverse Stock Split 2
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The Center ... hospital ROI on membership dues at 12.5. In other words, ... in value to member hospitals. The calculation used to determine ... , “This is the first time we’ve actually been ... methodology is really sound,” said Bill Ryan , president ...
(Date:10/20/2014)... Houston, Texas (PRWEB) October 20, 2014 ... invited to present the key elements of his innovative ... visiting professor to plastic surgery residents and faculty at ... (UTMB) , where he, too, was once a medical ... of the largest private cosmetic plastic surgery practices in ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 The ... iPage ( http://www.top10bestseohosting.com/go/iPage/ ) and GreenGeeks are the ... excellent platforms for those who want to buy ... same time. , The IT manager of Top10BestSEOHosting.com ... the most recommended suppliers for everyone. A lot ...
(Date:10/19/2014)... Texas (PRWEB) October 20, 2014 ... development for Partial Seizure, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ... featured news and press releases. It also reviews ... Partial Seizure and special features on late-stage and ...
(Date:10/19/2014)... Recently, Fancyflyingfox.com, an innovative company that provides many ... latest designs of 2014 mother of the bride ... are offered with big discounts, up to 70% off. ... can enjoy this special offer. , Owing to ... become one of the leading brands in the global ...
Breaking Medicine News(10 mins):Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2
... site in a mouse brain well connected to other ... entire brainafter one injection of gene therapy. If these ... may have a potential method for gene therapy to ... neurological disorders, such as Tay-Sachs disease. , Researchers from ...
... to Health Coverage Expected to Increase for Small Business Owners ... http://www.bluecrossca.com/click4biz ... business sector,is one of the fastest growing segments of California,s ... provide their,employees with health insurance. Blue Cross of California has ...
... in antioxidant vitamins and minerals does not seem to prevent ... finds a study published on bmj.com today. , ... loss in older people. It is caused by the progressive ... in the centre of the retina at the back of ...
... MONICA, Calif., Oct. 8 Proposed,regulations that would ... stem cell research grants to for-profit organizations fail,to ... for California taxpayers,paying for the research, the Foundation ... "To ensure that the people who have paid ...
... fitness,and healthy living in communities across the USA, is ... held in conjunction with the 30th,anniversary of the Detroit ... Expo, which runs Oct. 19-20 at Cobo,Center, exemplifies that ... that provide services to runners. The Detroit Free ...
... Veterinary Medical Association awarded its 2007 Student/Recent,Graduate Award, ... in Lacey. (Logo: http://www.newscom.com/cgi-bin/prnh/20070613/WSVMALOGO ), ... of his dedication to,organized veterinary medicine in Washington. ... Veterinary Medicine, he has served as a,member of ...
Cached Medicine News:Health News:One shot of gene therapy spreads through brain in animal study 2Health News:One shot of gene therapy spreads through brain in animal study 3Health News:New Online Tool Makes Enrollment in Blue Cross of California Easier 2Health News:Antioxidants do not prevent degenerative eye disease 2Health News:Revised California Stem Cell Research Rules Fail to Ensure Affordable Access to Cures, Consumers Warn 2Health News:Saturn Shows Its Commitment to Health and Fitness by Becoming Expo Title Sponsor for The Detroit Free Press/Flagstar Marathon 2Health News:Lacey Veterinarian Awarded 2007 WSVMA Recent Graduate Award 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: